[1]史建强,胡 云.扶正解毒汤辅助克唑替尼对晚期非小细胞肺癌患者临床疗效及对血清肿瘤标志物的影响[J].医学信息,2023,36(16):137-140.[doi:10.3969/j.issn.1006-1959.2023.16.027]
　SHI Jian-qiang,HU Yun.Clinical Efficacy of Fuzheng Jiedu Decoction Combined with Crizotinib in the Treatment of Patients with Advanced Non-small Cell Lung Cancer and its Effect on Serum Tumor Markers[J].Journal of Medical Information,2023,36(16):137-140.[doi:10.3969/j.issn.1006-1959.2023.16.027]
点击复制

扶正解毒汤辅助克唑替尼对晚期非小细胞肺癌患者临床疗效及对血清肿瘤标志物的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年16期
页码:
137-140
栏目:
论著
出版日期:
2023-08-15

文章信息/Info

Title:
Clinical Efficacy of Fuzheng Jiedu Decoction Combined with Crizotinib in the Treatment of Patients with Advanced Non-small Cell Lung Cancer and its Effect on Serum Tumor Markers
文章编号:
1006-1959（2023）16-0137-04
作者:
史建强; 胡 云
（余干县人民医院肿瘤科，江西 余干 335100）
Author(s):
SHI Jian-qiang; HU Yun
(Department of Oncology,Yugan County People’s Hospital,Yugan 335100,Jiangxi,China)
关键词:
扶正解毒汤; 克唑替尼; 晚期非小细胞肺癌; 肿瘤标志物
Keywords:
Fuzheng Jiedu decoction; Crizotinib; Advanced non-small cell lung cancer; Tumor markers
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.16.027
文献标志码:
A
摘要:
目的 研究扶正解毒汤辅助克唑替尼对晚期非小细胞肺癌患者临床疗效及对肿瘤标志物水平的影响。方法 选取2020年3月-2021年3月在我院诊治的62例晚期非小细胞肺癌患者为研究对象。采用随机数字表法分为对照组和观察组，各组31例。对照组采用克唑替尼治疗，观察组在对照组基础上应用扶正解毒汤治疗。比较两组临床治疗总有效率、血清肿瘤标志物[糖类抗原125（CA125）、癌胚抗原（CEA）]、肺功能指标[用力肺活量（FVC）、第1秒钟用力呼气容积（FEV1）]、免疫功能指标（T淋巴细胞亚群CD4+、CD8+）、毒副反应发生率、无进展生存期。结果 观察组治疗总有效率为87.10%，高于对照组的70.97%（P＜0.05）；两组治疗后血清CA125、CEA水平均低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后FVC、FEV1均高于治疗前，且观察组高于对照组（P＜0.05）；两组治疗后CD4+均低于治疗前，CD8+均高于治疗前，但观察组CD4+、CD8+均高于对照组（P＜0.05）；观察组毒副反应发生率为19.35%，低于对照组的41.94%（P＜0.05）；随访1年，观察组平均无进展生存期高于对照组（P＜0.05）。结论 扶正解毒汤辅助克唑替尼资料晚期非小细胞肺癌可一定程度提高近期疗效，降低肿瘤标志物水平，减轻临床毒副反应，延迟患者生存期，改善患者免疫功能和肺功能指标，有效促进病情的控制或延缓发展，进一步改善患者预后，值得临床应用。
Abstract:
Objective To study the clinical efficacy of Fuzheng Jiedu decoction combined with crizotinib in patients with advanced non-small cell lung cancer and its effect on the level of tumor markers.Methods A total of 62 patients with advanced non-small cell lung cancer diagnosed and treated in our hospital from March 2020 to March 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 31 patients in each group. The control group was treated with crizotinib, and the observation group was treated with Fuzheng Jiedu decoction on the basis of the control group. The total effective rate of clinical treatment, serum tumor markers [carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA)], lung function indicators [forced vital capacity (FVC), forced expiratory volume in the first second (FEV1)], immune function indicators (T lymphocyte subsets CD4+, CD8+), incidence of toxic and side effects, and progression-free survival were compared between the two groups.Results The total effective rate of treatment in the observation group was 87.10%, which was higher than 70.97% in the control group (P＜0.05). After treatment, the levels of serum CA125 and CEA in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P＜0.05). After treatment, FVC and FEV1 in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P＜0.05). After treatment, CD4+ in the two groups was lower than that before treatment, CD8+ was higher than that before treatment, but CD4+ and CD8+ in the observation group were higher than those in the control group (P＜0.05). The incidence of toxic and side effects in the observation group was 19.35%, which was lower than 41.94% in the control group (P＜0.05). After 1 year of follow-up, the average progression-free survival of the observation group was higher than that of the control group (P＜0.05).Conclusion Fuzheng Jiedu decoction combined with crizotinib in the treatment of advanced non-small cell lung cancer can improve the short-term efficacy to a certain extent, reduce the level of tumor markers, reduce the clinical toxic and side effects, delay the survival time of patients, improve the immune function and lung function indexes of patients, effectively promote the control or delay the development of the disease, and further improve the prognosis of patients, which is worthy of clinical application.

参考文献/References:

[1]黄婉怡,朱丽华,侯宛昕,等.老年晚期非小细胞肺癌的生存研究及影响因素分析[J].世界中医药,2019,14(1):214-219.[2]衣学新,邓军吉.益气养阴方对非小细胞肺癌患者化疗后免疫功能的影响[J].环球中医药,2018,11(6):935-938.[3]Lee SS,Cheah YK.The interplay between micrornas and cellular components of tumour microenvironment(TME)on non small-cell lung cancer(NSCLC)progression[J].J Immunol Res,2019,2019:3046379.[4]吴皓,李萍奥希替尼联合放化疗治疗晚期非小细胞肺癌患者的临床疗效及安全性分析[J].中国肿瘤临床与康复,2020,27(4):22-25.[5]王丽红,窦亚平,韩双双,等.非小细胞肺癌中Pokemon蛋白与P14ARF-MDM2-p53通路蛋白的相关性研究[J].国际呼吸杂志,2020,40(4):279-284.[6]朱礼阳,许春伟,于忠和.克唑替尼对ALK阳性非小细胞肺癌脑转移的疗效分析[J].临床与病理杂志,2018,36(9):1293-1296.[7]梁红格,徐燕,钟巍,等.克唑替尼在ALK阳性晚期NSCLC患者中的疗效和安全性评价及其预后影响因素[J].国际肿瘤学杂志,2017,44(5):336-341.[8]王文娴,宋正波,余新民,等.克唑替尼治疗28例间变性淋巴瘤激酶阳性晚期非小细胞肺癌疗效分析[J].中华肿瘤杂志,2018,21(10):784-787.[9]朱礼阳,于忠和,许春伟.克唑替尼对比化疗在中晚期非小细胞肺癌患者中的疗效分析[J].临床肺科杂志,2017,21(12):2139-2141.[10]毕国放,梁宇光,曲恒燕.克唑替尼在非小细胞肺癌治疗中耐药问题的研究状况[J].中国临床药理学杂志,2016,32(10):952-955.[11]姜媛利.克唑替尼治疗ALK阳性非小细胞肺癌脑转移的效果分析[J].河南医学研究,2017,25(10):1881-1882.[12]Xu L,Xu XH,Yuan C,et al.Clinical efficacy of icotinib in pa tients with advanced nonsquamous non-small cell lung cancer with un known EGFR mutation status that failed to respond to second-line chemotherapy[J].Ann Transl Med,2018,6(20):405.[13]朱丽华,陈尚雅,李和根,等.晚期非小细胞肺癌中医药联合外治法的临床研究[J].世界中医药,2017,12(1):34-36,41.[14]丁惠卿,赵莹,吕克,等.扶正解毒汤对晚期非小细胞肺癌患者肺功能改善的效果观察[J].河北中医,2017,38(11):1656-1659.[15]赵海燕,苏乌云,呼群,等.DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及对免疫功能的影响[J].现代生物医学进展,2017,17(13):2560-2564.[16]赵蜜,赵杰.扶正解毒汤联合GP化疗治疗中晚期非小细胞肺癌疗效观察[J].现代中西医结合杂志,2017,26(36):4045-4047.[17]鞠立霞,韩明权,张素芳,等.培元固本中药序贯化疗对晚期非小细胞肺癌免疫功能的影响[J].辽宁中医杂志,2018,43(11):2310-2312.[18]惠卿,赵蜜,赵莹,等.扶正解毒汤对肺癌晚期患者生活质量影响的临床观察[J].中医临床研究,2017,8(33):138-139.[19]段敏,贾春芳,段昕.益气固本汤联合DC方案化疗对局部晚期非小细胞肺癌患者血清肿瘤标志物、炎性因子及免疫功能的影响[J].海南医学院学报,2018,24(1):79-82.[20]宋伟祥,刘玉金,李浏博.“清肺消积方”配合介入化疗治疗老年晚期肺癌30例临床研究[J].江苏中医药,2018,50(4):34-37.

相似文献/References:

[1]牙韩达,韦亚娜,吴 燕.克唑替尼治疗非小细胞肺癌的研究[J].医学信息,2019,32(21):43.[doi:10.3969/j.issn.1006-1959.2019.21.015]
　YA Han-da,WEI Ya-na,WU Yan.Crizotinib in the Treatment of Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(16):43.[doi:10.3969/j.issn.1006-1959.2019.21.015]
[2]于海洋,潘跃银.D-二聚体及FIB对ALK阳性并服用克唑替尼治疗的肺癌患者无进展生存期的预测价值[J].医学信息,2023,36(03):77.[doi:10.3969/j.issn.1006-1959.2023.03.016]
　YU Hai-yang,PAN Yue-yin.The Predictive Value of D-dimer and FIB for Progression-free Survival in ALK-positive Lung Cancer Patients Treated with Crizotinib[J].Journal of Medical Information,2023,36(16):77.[doi:10.3969/j.issn.1006-1959.2023.03.016]

更新日期/Last Update: 1900-01-01